Today: 20 March 2026
Subscribe
Browse Category

LSE:LSEG.L 8 December 2025 - 12 January 2026

Why LSEG stock is ticking higher today after a buyback filing — and what investors watch next

Why LSEG stock is ticking higher today after a buyback filing — and what investors watch next

LSEG shares rose 0.6% to 9,096 pence by 0920 GMT Tuesday after the company bought back 112,769 shares on Monday at an average price of 8,885.77 pence, planning to cancel them. The stock remains 26% below its 52-week high despite recent gains. FTSE 100 closed above 10,000 for the first time on Monday. LSEG will have 510.2 million shares in issue after the cancellation.
6 January 2026
··
Most Active UK Stocks Today (9 December 2025): BP, Barclays, Rolls‑Royce, Unilever and More in Focus

Most Active UK Stocks Today (9 December 2025): BP, Barclays, Rolls‑Royce, Unilever and More in Focus

The FTSE 100 closed down 0.2% at 9,645.09 on Monday, with heavy trading concentrated in BP, Barclays, Rolls-Royce, Unilever, Lloyds, HSBC, London Stock Exchange Group, Anglo American, GSK, and British American Tobacco. Investors pulled back ahead of key US Federal Reserve and Bank of England rate decisions. FTSE 100 futures hovered near 9,657 early Tuesday, with technical signals pointing to caution.
9 December 2025
···········
London Stock Exchange Group (LSEG) Stock: ChatGPT Deal, £1bn Buyback and 2026 Price Targets – December 8, 2025

London Stock Exchange Group (LSEG) Stock: ChatGPT Deal, £1bn Buyback and 2026 Price Targets – December 8, 2025

London Stock Exchange Group shares traded at 8,643.91p on December 5, near the lower half of their 52-week range. The company bought back 194,084 shares at an average price of 8,675.32p as part of a £1 billion buyback. Analysts see 40–50% upside, but valuation models suggest the shares are expensive, with some estimating fair value far below current levels.
8 December 2025
··
1 2

Stock Market Today

  • Kessler Topaz Meltzer & Check Files Securities Fraud Class Action Against Soleno Therapeutics
    March 20, 2026, 1:23 PM EDT. Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO) concerning purchases of SLNO stock between March 26 and November 4, 2025. The lawsuit alleges that Soleno made materially false statements and omissions about safety concerns in its Phase 3 clinical trial for diazoxide choline extended-release tablets used to treat hyperphagia linked to Prader-Willi syndrome. The firm claims the company concealed issues relating to excess fluid retention in trial participants. Investors have until May 5, 2026, to seek lead plaintiff status. The complaint is pending in the U.S. District Court for the Northern District of California under case number 3:26-cv-01979. Investors who suffered losses are urged to contact the law firm for legal options at no cost.
Go toTop